3 Dutch companies, ProQR, UniQure and arGEN-X went public and raised approximately USD 272.5M combined. Nonetheless, the Biotech industry in the Netherlands has faced a drop in financing value of more than 50% whilst the number of rounds has decreased by 21%. The number of Biotech companies in the Netherlands has however increased significantly, from 280 in 2014 to 411 in 2015. Lastly, Prosensa Holding N.V, the Dutch biopharmaceutical company made headlines when it was acquired by BioMarin Pharmaceutical Inc. in a deal worth up to USD 840M.
Click here to download the Dutch Life Sciences Trend Analysis 2015 – 14 pages
Looking for your next Biotech or Medtech partner?
Use Biotechgate to identify new leads, licensing opportunities and management details.